

POSTER PRESENTATION

Open Access

Immunotherapy targeting esophageal cancer stem cells

Dongli Yue^{1,2}, Hongzheng Ren^{1,3}, Lan Huang^{1,2}, Yi Zhang^{1,2*}

From Society for Immunotherapy of Cancer 28th Annual Meeting National Harbor, MD, USA. 8-10 November 2013

Esophageal cancer is one of most common malignancies. Cancer stem cells (CSC) are considered to be resistant to chemotherapy and radiotherapy, which might be associated with the recurrence of the tumor after treatment. To find the therapeutic procedures targeting CSCs, the different methods have been used to identify the esophageal CSC-related genes and surface markers. The esophageal CSCs were found to resist the chemotherapy and the mechanism was explored as well. We also found the levels of tumor associated antigens in esophageal CSCs have differences comparing with the non-stem cancer cells. To understand if the tumor associated antigens can be used as targets by immune cells, we cloned the tumor antigen specific T cells and analyzed the T cell recognition of esophageal CSC both in vitro and in vivo. We found that the immunotherapy might be one of the optimal procedures targeting both non-stem cancer cells and esophageal CSC.

Authors' details

¹The Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ²The Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ³The Department of Oncology, The Center Hospital of Kaifeng, Henan University, Kaifeng, China.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P178

Cite this article as: Yue et al.: Immunotherapy targeting esophageal cancer stem cells. Journal for ImmunoTherapy of Cancer 2013 1(Suppl 1): P178.

¹The Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Full list of author information is available at the end of the article

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



